MCID: MYX013
MIFTS: 46

Myxofibrosarcoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Myxofibrosarcoma

MalaCards integrated aliases for Myxofibrosarcoma:

Name: Myxofibrosarcoma 11 58 14 75
Fibromyxosarcoma 58 71
Dermatofibrosarcoma Protuberans, Myxoid 71
Myxoid Malignant Fibrous Histiocytoma 58
Fibromyxoid Sarcoma 11

Characteristics:


Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:0080534
NCIt 49 C6496
ICD10 via Orphanet 32 C49.9
UMLS via Orphanet 72 C3714524
Orphanet 58 ORPHA79105
UMLS 71 C0334454 C3714524

Summaries for Myxofibrosarcoma

Orphanet: 58 A rare soft tissue sarcoma characterized by a malignant, fibroblastic lesion with variably myxoid stroma, pleomorphism, and a distinctively curvilinear vascular pattern. The majority of tumors arise in the limbs including the limb girdles, more often in dermal/subcutaneous tissues than in the underlying fascia and skeletal muscle, and usually present as a slowly growing, painless mass. Depth of the lesion and tumor grade do not influence the high rate of local recurrence, while the percentage of metastasis and tumor-associated mortality are much higher in deep-seated and high-grade neoplasms.

MalaCards based summary: Myxofibrosarcoma, also known as fibromyxosarcoma, is related to cutaneous fibrous histiocytoma and fibrous histiocytoma. An important gene associated with Myxofibrosarcoma is CREB3L2 (CAMP Responsive Element Binding Protein 3 Like 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, bone and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and shRNA abundance <= 50%

Disease Ontology: 11 A sarcoma that arises from the soft tissue and is characterized by the presence of spindle-shaped cells, cellular pleomorphism, thin-walled blood vessels, fibrous septa, and myxoid stroma.

Wikipedia: 75 Myxofibrosarcoma (MFS), although a rare type of tumor, is one of the most common soft tissue sarcomas,... more...

Related Diseases for Myxofibrosarcoma

Diseases related to Myxofibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 402)
# Related Disease Score Top Affiliating Genes
1 cutaneous fibrous histiocytoma 31.4 SERPINA3 CD34 CALD1
2 fibrous histiocytoma 31.3 SERPINA3 FUS EWSR1 CD34 CALD1
3 malignant fibrous histiocytoma 31.2 SERPINA3 MYOG MDM2 KIT EWSR1 DDIT3
4 sarcoma 31.0 SSX2 SSX1 SS18 SERPINA3 MYOG MDM2
5 fibrosarcoma 30.9 KIT FUS EWSR1 CREB3L2 CREB3L1
6 sclerosing liposarcoma 30.9 MDM2 KIT CD34
7 ossifying fibromyxoid tumor 30.9 SS18 MUC4 EWSR1 CREB3L2
8 neurilemmoma 30.8 SERPINA3 KIT CD34 CALD1
9 connective tissue benign neoplasm 30.7 SERPINA3 MDM2 KIT EWSR1 CDK4 CD34
10 liposarcoma 30.7 STAT6 MYOG MDM2 FUS EWSR1 DDIT3
11 kidney sarcoma 30.6 TLE1 SSX2 SSX1 SS18 EWSR1
12 small intestinal sarcoma 30.6 KIT EWSR1
13 myoepithelial carcinoma 30.5 SS18 FUS EWSR1
14 retroperitoneal sarcoma 30.5 MYOG MDM2 KIT CDK4 CD34 CALD1
15 breast malignant phyllodes tumor 30.5 SERPINA3 KIT CD34
16 chondrosarcoma 30.5 SERPINA3 MDM2 EWSR1 CDK4
17 intravascular fasciitis 30.5 MUC4 KIT CD34 CALD1
18 breast sarcoma 30.5 MYOG KIT CD34
19 leiomyosarcoma 30.5 SERPINA3 MYOG MDM2 KIT CDK4
20 pleomorphic rhabdomyosarcoma 30.5 SERPINA3 MYOG MDM2
21 heart cancer 30.4 SS18 SERPINA3 MYOG MDM2 KIT CD34
22 peripheral nervous system neoplasm 30.4 SERPINA3 MDM2 KIT EWSR1 CD34
23 neurofibromatosis, type i 30.4 KIT EWSR1 CD34
24 hemangiopericytoma, malignant 30.4 STAT6 SSX2 SSX1 SERPINA3 NAB2 MDM2
25 vagina sarcoma 30.4 STAT6 MYOG KIT CD34 CALD1
26 gastrointestinal stromal tumor 30.3 SSX2 SS18 SERPINA3 MDM2 KIT EWSR1
27 perineurioma 30.3 KIT CREB3L2 CD34
28 leukemia, acute myeloid 30.3 SERPINA3 MDM2 KIT EWSR1 CDK4 CD34
29 rhabdomyosarcoma 30.2 SSX2 SSX1 MYOG MDM2 KIT FUS
30 endometrial stromal sarcoma 30.2 SSX2 SS18 MYOG KIT EWSR1 CD34
31 angiosarcoma 30.2 SERPINA3 MDM2 KIT CD34
32 glomus tumor 30.2 TLE1 KIT CD34 CALD1
33 desmoid tumor 30.2 MDM2 KIT CD34 CALD1
34 sarcomatoid squamous cell skin carcinoma 30.2 SERPINA3 MYOG CD34 CALD1
35 extraosseous osteosarcoma 30.2 SSX1 MYOG MDM2 KIT CDK4 CD34
36 meningioma, familial 30.2 STAT6 SERPINA3 NAB2 MDM2 KIT EWSR1
37 malignant peripheral nerve sheath tumor 30.1 MYOG MDM2 KIT CDK4 CD34
38 pleomorphic lipoma 30.1 MDM2 FUS EWSR1 DDIT3 CDK4 CD34
39 sarcomatoid mesothelioma 30.1 TLE1 SSX2 SSX1 SS18 NAB2
40 rhabdomyosarcoma 2 30.1 SSX2 SSX1 SS18 MYOG MDM2 KIT
41 heart sarcoma 30.1 SSX2 SSX1 SS18 SERPINA3 MYOG MDM2
42 pseudosarcomatous fibromatosis 30.0 STAT6 SS18 SERPINA3 NAB2 MYOG MUC4
43 dermatofibrosarcoma protuberans 30.0 TLE1 SSX2 SSX1 SS18 SERPINA3 NAB2
44 mesenchymal cell neoplasm 30.0 STAT6 SSX2 SS18 SERPINA3 NAB2 MYOG
45 lipomatosis, multiple 30.0 SERPINA3 NAB2 MDM2 KIT FUS EWSR1
46 mediastinal cancer 29.9 KIT CD34
47 sarcoma, synovial 29.9 TLE1 SSX2 SSX1 SS18 NAB2 MYOG
48 myxoid liposarcoma 29.9 STAT6 SSX2 SSX1 SS18 NAB2 MDM2
49 vascular cancer 29.9 STAT6 SERPINA3 NAB2 MYOG KIT EWSR1
50 cellular myxoid liposarcoma 29.8 SSX2 SSX1 SS18 SERPINA3 MDM2 FUS

Graphical network of the top 20 diseases related to Myxofibrosarcoma:



Diseases related to Myxofibrosarcoma

Symptoms & Phenotypes for Myxofibrosarcoma

GenomeRNAi Phenotypes related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

25 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.2 SSX2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.2 SSX2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.2 EWSR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.2 TLE1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.2 FUS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.2 SSX1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.2 TLE1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.2 TLE1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.2 TLE1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.2 SSX1 SSX2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.2 EWSR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.2 FUS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.2 EWSR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.2 EWSR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.2 FUS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.2 SSX2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-203 10.2 EWSR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-206 10.2 SSX1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.2 FUS
20 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.2 SSX2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.2 FUS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-40 10.2 FUS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.2 EWSR1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.2 TLE1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.2 SSX1 TLE1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.2 SSX1 SSX2 TLE1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.2 FUS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.2 TLE1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.2 CDK4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-89 10.2 EWSR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.2 EWSR1
32 no effect GR00402-S-1 10.19 CALD1 CD34 CDK4 CREB3L1 CREB3L2 DDIT3
33 no effect GR00402-S-2 10.19 CALD1 CD34 CDK4 CREB3L2 DDIT3 EWSR1
34 shRNA abundance <= 50% GR00343-S 9.63 CDK4 CREB3L1 CREB3L2 DDIT3 FUS NAB2

MGI Mouse Phenotypes related to Myxofibrosarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 CD34 CDK4 CREB3L1 DDIT3 EWSR1 FUS
2 neoplasm MP:0002006 9.86 CD34 CDK4 DDIT3 EWSR1 KIT MDM2
3 growth/size/body region MP:0005378 9.8 CALD1 CDK4 CREB3L1 CREB3L2 DDIT3 EWSR1
4 integument MP:0010771 9.28 CD34 CDK4 EWSR1 KIT MDM2 MYOG

Drugs & Therapeutics for Myxofibrosarcoma

Drugs for Myxofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 34)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
4
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
5
Palifosfamide Investigational Phase 2, Phase 3 31645-39-3 100427
6 Anti-Bacterial Agents Phase 2, Phase 3
7 Antibiotics, Antitubercular Phase 2, Phase 3
8 Liposomal doxorubicin Phase 2, Phase 3
9
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
10
Ipilimumab Approved Phase 2 477202-00-9
11
Melphalan Approved Phase 2 148-82-3 4053 460612
12
Dactinomycin Approved, Investigational Phase 2 50-76-0 2019 457193
13
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
14
Dexrazoxane Approved, Withdrawn Phase 2 24584-09-6 71384
15
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
16
Topotecan Approved, Investigational Phase 1, Phase 2 123948-87-8, 119413-54-6 60699 60700
17 Antibodies, Monoclonal Phase 2
18 Antiemetics Phase 2
19 Anesthetics Phase 2
20 Emetics Phase 2
21 Cardiotonic Agents Phase 2
22
Razoxane Phase 2
23 Protective Agents Phase 2
24 Alkylating Agents Phase 1, Phase 2
25 Antineoplastic Agents, Alkylating Phase 1, Phase 2
26 Antirheumatic Agents Phase 1, Phase 2
27 topoisomerase I inhibitors Phase 1, Phase 2
28
Avelumab Approved, Investigational Phase 1 1537032-82-8
29
Nivolumab Approved Phase 1 946414-94-4
30 Immunoglobulins Phase 1
31 Immune Checkpoint Inhibitors Phase 1
32 Antibodies Phase 1
33 Antineoplastic Agents, Immunological Phase 1
34 Poly I-C Phase 1

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
2 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Unknown status NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
3 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
4 ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy Recruiting NCT04480502 Phase 2 Ipilimumab
5 A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma Recruiting NCT04332874 Phase 2 Pembrolizumab;infusion of melphalan and dactinomycin
6 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
7 A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Enrolling by invitation NCT05266196 Phase 1, Phase 2 Seclidemstat
8 A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma Terminated NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib
9 A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Withdrawn NCT04906876 Phase 2 Gemcitabine;Docetaxel;9-ING-41
10 A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Withdrawn NCT05116800 Phase 2 Gemcitabine;9-ING-41;Docetaxel
11 A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas Active, not recruiting NCT03009201 Phase 1 Doxorubicin Hydrochloride;Ribociclib
12 A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma Active, not recruiting NCT04242238 Phase 1 DCC-3014;Avelumab
13 A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma Active, not recruiting NCT04420975 Phase 1
14 Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group Recruiting NCT03967834

Search NIH Clinical Center for Myxofibrosarcoma

Genetic Tests for Myxofibrosarcoma

Anatomical Context for Myxofibrosarcoma

Organs/tissues related to Myxofibrosarcoma:

MalaCards : Skeletal Muscle, Bone, Breast, Small Intestine, Lung, Smooth Muscle, Kidney

Publications for Myxofibrosarcoma

Articles related to Myxofibrosarcoma:

(show top 50) (show all 1074)
# Title Authors PMID Year
1
Clinical considerations of bleomycin based electrochemotherapy with variable electrode geometry electrodes for inoperable, deep-seated soft tissue sarcomas. 62
35987061 2022
2
Low-grade fibromyxoid sarcoma in labial mucosa: Report of a rare case in a pediatric patient. 62
36384080 2022
3
Low-grade fibromyxoid sarcoma arising in the mediastinum: Case report and review of the literature. 62
36238210 2022
4
Pleomorphic Liposarcoma: A Series of 120 Cases With Emphasis on Morphologic Variants. 62
36006773 2022
5
Giant primary low-grade fibromyxoid sarcoma arising from the left pulmonary parenchyma: A case report and literature review. 62
36148539 2022
6
Low-grade fibromyxoid sarcoma of the vulva presenting as a cystic mass: A case report and review of literature. 62
36252544 2022
7
Usefulness of SynCAM3 and cyclin D1 immunohistochemistry in distinguishing superficial CD34-positive fibroblastic tumor from its histological mimics. 62
36344703 2022
8
Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma. 62
35947340 2022
9
A rare case of primary myxofibrosarcoma of the right kidney. 62
35637116 2022
10
Epidemiologic Survey of Myxofibrosarcoma Using Data from the Bone and Soft Tissue Tumor Registry in Japan. 62
36437410 2022
11
Low-grade fibromyxoid sarcoma of the orbit. 62
36437749 2022
12
Approach to FNA of Myxoid Soft Tissue Tumors. 62
35878421 2022
13
Patient-Specific Sarcoma Organoids for Personalized Translational Research: Unification of the Operating Room with Rare Cancer Research and Clinical Implications. 62
35780216 2022
14
TRAF7-mutated Fibromyxoid Spindle Cell Tumors Are Associated With an Aggressive Clinical Course and Harbor an Undifferentiated Sarcoma Methylation Signature: A Molecular and Clinicopathologic Study of 3 Cases. 62
36395468 2022
15
Imaging of soft tissue sarcomas of the extremities with radiologic-pathologic correlation. 62
35654634 2022
16
Novel low-grade renal spindle cell neoplasm with HEY1::NCOA2 fusion that is distinct from mesenchymal chondrosarcoma. 62
36416671 2022
17
Low-grade Fibromyxoid Sarcoma With Heterotopic Bone Formation: Case Report and Review of the Literature. 62
36121293 2022
18
Histology-Specific Prognostication for Radiation-Associated Soft Tissue Sarcoma. 62
36240470 2022
19
Primary low-grade fibromyxoid sarcoma of the mediastinum: A case report. 62
35584992 2022
20
Low-Grade Fibromyxoid Sarcomas with the Maxillary Sinus Localization: A Case Report and Review of the Literature. 62
36452748 2022
21
Molecular and clinicopathological analysis revealed an immuno-checkpoint inhibitor as a potential therapeutic target in a subset of high-grade myxofibrosarcoma. 62
35705750 2022
22
CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response. 62
36221119 2022
23
Low-grade Fibromyxoid Sarcoma of the Vulva and Vagina: Clinical, Pathologic, and Molecular Characterization of 7 Cases and Review of the Literature. 62
35617488 2022
24
Superficial low-grade fibromyxoid sarcoma. 62
36074249 2022
25
Pleomorphic liposarcoma: A clinicopathologic study of 20 FNA cases. 62
35447010 2022
26
Characterizing inflammatory markers in highly aggressive soft tissue sarcomas. 62
36181081 2022
27
Clinicopathological profile of myxoid soft tissue tumors- A retrospective study in a tertiary care hospital in South India. 62
36149223 2022
28
Concomitant anomalous coronary artery and a large primary myxofibrosarcoma of the heart. 62
35043521 2022
29
Nodular fasciitis arising from the buccal region after segmentectomy with rapid growth mimicking postirradiation myxofibrosarcoma: A case report. 62
36123836 2022
30
Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. 62
35767280 2022
31
A Unique Presentation of Pulmonary Vein Thrombosis in a Patient With Rapidly Progressive Metastatic Pelvic Myxofibrosarcoma. 62
36225433 2022
32
Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa). 62
35218514 2022
33
Myxofibrosarcoma: Another mimicker of meningioma. 62
36084960 2022
34
The landscape of genetic aberrations in myxofibrosarcoma. 62
35484982 2022
35
Angiofibroma of soft tissue: Current status of pathology and genetics. 62
35211945 2022
36
[Paratesticular Low-Grade Fibromyxoid Sarcoma: A Case Report]. 62
36071020 2022
37
Neoadjuvant Radiation in High-Grade Soft-Tissue Sarcomas: Histopathologic Features and Response Evaluation. 62
35687332 2022
38
Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. 62
35153104 2022
39
GLUT-1 expression is helpful to distinguish myxofibrosarcoma from nodular fasciitis. 62
35792526 2022
40
Primary thyroid gland myxofibrosarcoma: a case report and review of the literature. 62
35876910 2022
41
The emerging PRRX1-NCOA fibroblastic neoplasm: a combined reappraisal of published tumors and two new cases. 62
34647172 2022
42
Ankle joint salvage surgery with an ipsilateral mid-fibula osteocutaneous free flap and contralateral anterolateral thigh free flap: A case report and literature review. 62
35083775 2022
43
Clinical, pathologic, and molecular analyses of superficial low-grade fibromyxoid sarcoma in two young patients: A rare and deceptive mimic of benignancy. 62
35191077 2022
44
Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. 62
35715142 2022
45
Review of primary superficial soft tissue mesenchymal tumors of malignant or intermediate biological potential. 62
35867123 2022
46
Rare Mimic of a Myxofibrosarcoma: Cutaneous Myxoid Spindle Cell Squamous Cell Carcinoma as a Complication of Chronic Osteomyelitis. 62
35315369 2022
47
Glomus Tumor of the Lower Extremity Previously Misdiagnosed as Complex Regional Pain Syndrome in Close Proximity to a Myxofibrosarcoma: A Case Report. 62
35797605 2022
48
Differential diagnosis of myxoid soft tissue tumors. Experience in the Clinical University Hospital of Valencia. 62
35779885 2022
49
Esophageal extraskeletal neoplasm Ewing's sarcoma: Case report. 62
35926382 2022
50
Robotic-assisted surgery for esophageal submucosal tumors: a single-center case series. 62
35147859 2022

Variations for Myxofibrosarcoma

Cosmic variations for Myxofibrosarcoma:

8 (show all 12)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM89629521 SF3B1 soft tissue,blood vessel,other,neoplasm c.2014G>T p.A672S 2:197402619-197402619 3
2 COSM87508264 NCOR1 soft tissue,blood vessel,other,neoplasm c.3838G>T p.G1280W 17:16072202-16072202 3
3 COSM101155459 NCOR1 soft tissue,blood vessel,other,neoplasm c.3886G>T p.G1296W 17:16072202-16072202 3
4 COSM101210927 NCOR1 soft tissue,blood vessel,other,neoplasm c.3559G>T p.G1187W 17:16072202-16072202 3
5 COSM144457442 MSH6 soft tissue,blood vessel,other,neoplasm c.2309G>A p.G770D 2:47803462-47803462 3
6 COSM131472690 MSH6 soft tissue,blood vessel,other,neoplasm c.2309G>A p.G770D 2:47803462-47803462 3
7 COSM85779643 MSH6 soft tissue,blood vessel,other,neoplasm c.3215G>A p.G1072D 2:47803462-47803462 3
8 COSM144639336 MSH6 soft tissue,blood vessel,other,neoplasm c.119G>A p.G40D 2:47803462-47803462 3
9 COSM132100831 MSH6 soft tissue,blood vessel,other,neoplasm c.2825G>A p.G942D 2:47803462-47803462 3
10 COSM85400395 MAP2K2 soft tissue,blood vessel,other,neoplasm c.979A>G p.N327D 19:4097284-4097284 3
11 COSM101413162 MAP2K2 soft tissue,blood vessel,other,neoplasm c.688A>G p.N230D 19:4097284-4097284 3
12 COSM106234905 FBXO11 soft tissue,blood vessel,other,neoplasm c.169+4733C>T p.? 2:47803462-47803462 3

Copy number variations for Myxofibrosarcoma from CNVD:

6 (show all 47)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 29705 1 234600000 241700000 Loss AKT3 Myxofibrosarcoma
2 38875 10 105700000 114900000 Loss ACSL5 Myxofibrosarcoma
3 39423 10 114900000 127400000 Loss DMBT1 Myxofibrosarcoma
4 42687 10 3800000 6700000 Loss TRDMT1 Myxofibrosarcoma
5 47803 10 98000000 105700000 Loss TLX1 Myxofibrosarcoma
6 47805 10 98000000 105700000 Loss PLAU Myxofibrosarcoma
7 49687 11 110000000 120700000 Loss CEP57 Myxofibrosarcoma
8 51757 11 130300000 134452384 Loss ADAMTS8 Myxofibrosarcoma
9 54382 11 43400000 48800000 Loss CD82 Myxofibrosarcoma
10 61474 12 1 14800000 Gain CCND2 Myxofibrosarcoma
11 61522 12 1 33200000 Loss LRP6 Myxofibrosarcoma
12 66186 12 26300000 33200000 Gain SSPN Myxofibrosarcoma
13 70913 12 66000000 69800000 Gain HMGA2 Myxofibrosarcoma
14 73112 12 91200000 94800000 Loss BTG1 Myxofibrosarcoma
15 108897 17 23200000 35400000 Loss LIG3 Myxofibrosarcoma
16 115128 17 54900000 59900000 Gain TBX2 Myxofibrosarcoma
17 124176 19 1 6900000 Gain SH3GL1 Myxofibrosarcoma
18 143681 2 23900000 31900000 Loss ALK Myxofibrosarcoma
19 147727 2 69800000 136600000 Loss CXCR4 Myxofibrosarcoma
20 148303 2 75400000 83700000 Loss REG1A Myxofibrosarcoma
21 151117 20 17800000 27100000 Loss JAG1 Myxofibrosarcoma
22 170894 3 161200000 184200000 Loss MECOM Myxofibrosarcoma
23 177567 3 58500000 63700000 Loss FHIT Myxofibrosarcoma
24 186568 4 36900000 114100000 Loss IBSP Myxofibrosarcoma
25 187541 4 50700000 52400000 Gain AFP Myxofibrosarcoma
26 208064 6 164400000 170899992 Loss PDCD2 Myxofibrosarcoma
27 217848 7 104755715 105039798 Amplificationlication SRPK2 Myxofibrosarcoma
28 217923 7 105888733 105925638 Amplificationlication NAMPT Myxofibrosarcoma
29 218114 7 107788083 108096826 Amplificationlication NRCAM Myxofibrosarcoma
30 218692 7 116312458 116438439 Amplificationlication MET Myxofibrosarcoma
31 219052 7 121513158 121702088 Amplificationlication PTPRZ1 Myxofibrosarcoma
32 219257 7 124462440 124570037 Amplificationlication POT1 Myxofibrosarcoma
33 219480 7 127292201 127732658 Amplificationlication SND1 Myxofibrosarcoma
34 219953 7 132400000 147500000 Gain ARHGEF5 Myxofibrosarcoma
35 223288 7 1855427 2272583 Amplificationlication MAD1L1 Myxofibrosarcoma
36 225548 7 47314752 47621742 Amplification TNS3 Myxofibrosarcoma
37 228044 7 73245192 73247014 Amplificationlication CLDN4 Myxofibrosarcoma
38 228772 7 81331444 81399452 Amplificationlication HGF Myxofibrosarcoma
39 229104 7 87257728 87461612 Amplificationlication RUNDC3B Myxofibrosarcoma
40 229332 7 90095737 90839904 Amplificationlication CDK14 Myxofibrosarcoma
41 229600 7 92234236 92465941 Amplificationlication CDK6 Myxofibrosarcoma
42 234953 8 140000000 146274826 Gain TG Myxofibrosarcoma
43 242385 8 7200000 43200000 Gain POLB Myxofibrosarcoma
44 262150 X 31500000 37500000 Gain OTC Myxofibrosarcoma
45 264432 X 65100000 67700000 Gain EDA Myxofibrosarcoma
46 264546 X 67700000 72200000 Gain NALF2 Myxofibrosarcoma
47 266520 X 98200000 110500000 Loss PLP1 Myxofibrosarcoma

Expression for Myxofibrosarcoma

Search GEO for disease gene expression data for Myxofibrosarcoma.

Pathways for Myxofibrosarcoma

Pathways related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.24 MDM2 KIT ITGA10 CREB3L2 CREB3L1 CDK4
2 11.41 MYOG KIT CD34
3
Show member pathways
11.21 MDM2 ITGA10 CREB3L2 CREB3L1 CDK4
4 11.12 DDIT3 CREB3L2 CREB3L1

GO Terms for Myxofibrosarcoma

Biological processes related to Myxofibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of DNA-templated transcription GO:0006355 9.53 TLE1 STAT6 SSX2 SSX1 NAB2 MYOG
2 endoplasmic reticulum unfolded protein response GO:0030968 9.43 DDIT3 CREB3L2 CREB3L1

Sources for Myxofibrosarcoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....